{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:53:41Z","timestamp":1775818421754,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1053\/j.ajkd.2012.07.028","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T05:31:08Z","timestamp":1352266268000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Treatment of Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathies: A Focus on Eculizumab"],"prefix":"10.1053","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct00904826","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00935883","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01029587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01095887","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01106027","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01221181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01303952","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01327573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01399593","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01403389","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01406288","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01410916","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jan","family":"Schmidtko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Peine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"El-Housseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2012.07.028_bib2","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib3","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.ajkd.2012.07.028_bib4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2012.07.028_bib7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany","volume":"365","author":"Frank","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib8","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1046\/j.1523-1755.1998.00943.x","article-title":"Endothelial cell activation","volume":"53","author":"Ballermann","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2012.07.028_bib10","first-page":"344","article-title":"Thrombotic microangiopathies, including hemolytic uremic syndrome","volume":"Vol 1","author":"Ruggenenti","year":"2010"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(52)90022-3","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease","volume":"13","author":"Moschcowitz","year":"1952","journal-title":"Am J Med"},{"issue":"22","key":"10.1053\/j.ajkd.2012.07.028_bib12","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.ajkd.2012.07.028_bib13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJM199811263392210","article-title":"Moschcowitz, multimers, and metalloprotease","volume":"339","author":"Moake","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.ajkd.2012.07.028_bib14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2012.07.028_bib15","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"issue":"20","key":"10.1053\/j.ajkd.2012.07.028_bib17","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"St\u00e5hl","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib18","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"St\u00e5hl","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.ajkd.2012.07.028_bib19","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2012.07.028_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1196\/annals.1352.032","article-title":"Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue","volume":"1056","author":"Atkinson","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2006-939767","article-title":"Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome","volume":"32","author":"Zimmerhackl","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"16","key":"10.1053\/j.ajkd.2012.07.028_bib22","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.molimm.2007.06.003","article-title":"Where next with atypical hemolytic uremic syndrome?","volume":"44","author":"Jokiranta","year":"2007","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1053\/j.ajkd.2012.07.028_bib23","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.4049\/jimmunol.180.9.6385","article-title":"A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity","volume":"180","author":"Blom","year":"2008","journal-title":"J Immunol"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0895-839","article-title":"Complement-specific antibodies: designing novel anti-inflammatories","volume":"1","author":"Matis","year":"1995","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2006-939769","article-title":"Platelet activation in hemolytic uremic syndrome","volume":"32","author":"Karpman","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1172\/JCI16651","article-title":"Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome","volume":"111","author":"Manuelian","year":"2003","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.2006091069","article-title":"Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells","volume":"18","author":"Heinen","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2012.07.028_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MNH.0b013e32833aff4a","article-title":"Thrombotic microangiopathies: new insights and new challenges","volume":"19","author":"Zipfel","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1053\/j.ajkd.2012.07.028_bib32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","article-title":"Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression","volume":"290","author":"Garg","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib33","first-page":"39","article-title":"Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome","volume":"46","author":"Gagnadoux","year":"1996","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2012.07.028_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/adc.80.3.214","article-title":"Neuropsychological sequelae of haemolytic uraemic syndrome","volume":"80","author":"Schlieper","year":"1999","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.1996.40","article-title":"Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma","volume":"49","author":"Remuzzi","year":"1996","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib37","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0022-3476(75)80235-6","article-title":"Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole","volume":"86","author":"Arenson","year":"1975","journal-title":"J Pediatr"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-86-1-102","article-title":"Antiplatelet treatment of thrombotic thrombocytopenic purpura","volume":"86","author":"Amorosi","year":"1977","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib39","first-page":"429","article-title":"Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP)","volume":"82","author":"Bobbio-Pallavicini","year":"1997","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib40","first-page":"130","article-title":"Antiplatelet therapy in thrombotic thrombocytopenic purpura","volume":"24","author":"del Zoppo","year":"1987","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib41","first-page":"659","article-title":"Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin","volume":"85","author":"Au","year":"2000","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-2008-1035620","article-title":"[Treatment of the hemolytic-uremic syndrome with streptokinase and heparin (author's translation)]","volume":"192","author":"Diekmann","year":"1980","journal-title":"Klin Padiatr"},{"issue":"48","key":"10.1053\/j.ajkd.2012.07.028_bib43","first-page":"1666","article-title":"[Microangiopathic hemolytic anemias. Clinical pattern, therapy and clinical course in 14 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome]","volume":"116","author":"Krause","year":"1986","journal-title":"Schweiz Med Wochenschr"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib44","first-page":"325","article-title":"Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins","volume":"80","author":"Centurioni","year":"1995","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.ajkd.2012.07.028_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","article-title":"Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura","volume":"84","author":"Reddy","year":"2005","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0955-3886(00)00073-4","article-title":"Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine","volume":"23","author":"Chamouni","year":"2000","journal-title":"Transfus Sci"},{"issue":"3","key":"10.1053\/j.ajkd.2012.07.028_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0955-3886(99)00092-2","article-title":"Cascade filtration for TTP: an effective alternative to plasma exchange with cryodepleted plasma","volume":"21","author":"Bruni","year":"1999","journal-title":"Transfus Sci"},{"issue":"12","key":"10.1053\/j.ajkd.2012.07.028_bib48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM198403223101206","article-title":"Therapeutic plasma exchange","volume":"310","author":"Shumak","year":"1984","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2012.07.028_bib50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1046\/j.1537-2995.1998.38998409003.x","article-title":"The use of plasma as a replacement fluid in plasma exchange","volume":"38","author":"Leblond","year":"1998","journal-title":"Transfusion (Paris)"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2012.07.028_bib51","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(02)00148-2","article-title":"Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes","volume":"107","author":"Barz","year":"2002","journal-title":"Thromb Res"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib52","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1600-6143.2006.01375.x","article-title":"Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation","volume":"6","author":"Saland","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2012.07.028_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1467-7652.2010.00552.x","article-title":"Production of biologically active recombinant human factor H in Physcomitrella","volume":"9","author":"B\u00fcttner-Mainik","year":"2011","journal-title":"Plant Biotechnol J"},{"issue":"9318","key":"10.1053\/j.ajkd.2012.07.028_bib54","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(02)08560-4","article-title":"Combined kidney and liver transplantation for familial haemolytic uraemic syndrome","volume":"359","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2012.07.028_bib57","series-title":"Solaris (eculizumab) [prescribing information]","year":"2012"},{"issue":"12","key":"10.1053\/j.ajkd.2012.07.028_bib58","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2012.07.028_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.blre.2007.10.002","article-title":"Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria","volume":"22","author":"Brodsky","year":"2008","journal-title":"Blood Rev"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib61","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib63","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-011-1989-4","article-title":"Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings","volume":"26","author":"Tschumi","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib64","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","article-title":"Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome","volume":"9","author":"Chatelet","year":"2009","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2012.07.028_bib65","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1172\/JCI118195","article-title":"Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation","volume":"96","author":"Rinder","year":"1995","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib66","first-page":"3441","article-title":"Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria [abstract]","volume":"112","author":"Kelly","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"10.1053\/j.ajkd.2012.07.028_bib67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1542\/peds.67.6.882","article-title":"Meningococcal meningitis in familial deficiency of the fifth component of complement","volume":"67","author":"Peter","year":"1981","journal-title":"Pediatrics"},{"issue":"5","key":"10.1053\/j.ajkd.2012.07.028_bib68","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","article-title":"Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency","volume":"63","author":"Ross","year":"1984","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0090-1229(90)90067-Z","article-title":"Combined complete C5 and partial C4 deficiency in humans: clinical consequences and complement-mediated functions in vitro","volume":"55","author":"Gianella-Borradori","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2012.07.028_bib70","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","article-title":"Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease","volume":"27","author":"Granoff","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"10.1053\/j.ajkd.2012.07.028_bib71","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/ng.640","article-title":"Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease","volume":"42","author":"Davila","year":"2010","journal-title":"Nat Genet"},{"issue":"9665","key":"10.1053\/j.ajkd.2012.07.028_bib72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.ajkd.2012.07.028_bib73","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMcp063561","article-title":"Clinical practice","volume":"355","author":"Gardner","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2012.07.028_bib74","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2012.07.028_bib75","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2012.07.028_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jtcvs.2010.08.035","article-title":"Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials","volume":"142","author":"Smith","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"10.1053\/j.ajkd.2012.07.028_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2012.07.028_bib78","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","article-title":"Eculizumab and refractory membranoproliferative glomerulonephritis","volume":"366","author":"Radhakrishnan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2012.07.028_bib79","first-page":"253","article-title":"Management of ANCA-associated vasculitis: current trends and future prospects","volume":"6","author":"Hamour","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"26","key":"10.1053\/j.ajkd.2012.07.028_bib80","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"issue":"9796","key":"10.1053\/j.ajkd.2012.07.028_bib81","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(11)61145-8","article-title":"Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study","volume":"378","author":"Colic","year":"2011","journal-title":"Lancet"},{"issue":"6035","key":"10.1053\/j.ajkd.2012.07.028_bib82","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1126\/science.332.6035.1249","article-title":"Germany","volume":"332","author":"Kupferschmidt","year":"2011","journal-title":"Science"},{"issue":"6051","key":"10.1053\/j.ajkd.2012.07.028_bib83","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.333.6051.1818","article-title":"Epidemiology","volume":"333","author":"Kupferschmidt","year":"2011","journal-title":"Science"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612012292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612012292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:59:35Z","timestamp":1759456775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638612012292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0272638612012292"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.028","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathies: A Focus on Eculizumab","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}